Foster City, California-based biopharmaceutical leader Gilead Sciences, Inc. (GILD), with a market cap of $84.1 billion, specializes in HIV/AIDS, liver diseases, oncology, and respiratory ailments. It is known for its breakthrough drugs with a focus on expanding through collaborations and acquisitions.
Shares of the biopharmaceutical company have significantly underperformed the broader market over the past 52 weeks. GILD has declined 13.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 26.6%. In 2024 alone, shares of GILD are down 16.6%, compared to SPX's 9.5% gains on a YTD basis.
